Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation

Rhea-AI Summary

Cadrenal Therapeutics (Nasdaq: CVKD) outlined a consolidated multi-indication strategy for its Cardiac Acute Critical Care franchise centered on CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI).

Following the discontinuation of a competitor’s late-stage Phase 3 CSA-AKI trial for lack of efficacy, the company is positioning CAD-1005, a 12-lipoxygenase (12-LOX) inhibitor, for first-in-class potential in the $1 billion+ U.S. CSA-AKI market. CAD-1005 is being studied as a “post-operative shield” intended to reduce platelet hyperactivation in HIT and inflammation-driven injury in CSA-AKI. Late-breaking Phase 2 data presented at ISTH 2026 showed an absolute reduction in thrombotic events greater than 25% with a favorable safety and renal-protective baseline. Cadrenal is pursuing global strategic partnerships, including out-licensing or co-development, for this Phase 3-ready critical care asset.

Positive

• Phase 2 thrombotic event reduction >25% with favorable safety and renal baseline
• $1 billion+ U.S. CSA-AKI market opportunity targeted with CAD-1005
• Phase 3-ready CAD-1005 positioned as first-in-class 12-LOX inhibitor for CSA-AKI and HIT

Negative

• None.

Argus Aug 3 session 11 alerts

-2.49% close to close 0.6x rel. volume Open Argus

Details

News Market Reaction – CVKD

+9.6% Peak in 28 hr 28 min

$6.72M Market Cap

In the Aug 3 session, CVKD declined 2.49%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.6% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The active S-3 resale registration covers 2,942,400 shares, adding documented financing overhang to ...

Analysis

The active S-3 resale registration covers 2,942,400 shares, adding documented financing overhang to this dual-indication strategy. Insider context shows Net Selling, while partnership execution and CSA-AKI development remain key factors to watch.

Key Figures

Thrombotic-event reduction: greater than 25% CSA-AKI market opportunity: $1 billion+ Competitor trial phase: Phase 3

Thrombotic-event reduction

greater than 25%

Late-breaking Phase 2 CAD-1005 data

CSA-AKI market opportunity

$1 billion+

U.S. CSA-AKI market

Competitor trial phase

Phase 3

Competitor CSA-AKI trial discontinued for lack of efficacy

Previous Clinical trial Reports

5 past events · Latest: Jul 13

Same Type 5 events

1. Jul 13

   Phase 2 clinical data

   24h Move

   -16.3%

   CAD-1005 reported greater than 25% thrombotic-event reduction in HIT

2. Jun 24

   Phase 2 presentation

   24h Move

   -2.6%

   CAD-1005 Phase 2 data received late-breaking oral presentation selection

3. Jun 03

   Partnering event

   24h Move

   -3.7%

   Cadrenal planned partnering meetings for Phase 3-ready CAD-1005

4. Apr 30

   FDA Phase 3 path

   24h Move

   +19.3%

   FDA meeting supported a pivotal Phase 3 registration trial for CAD-1005

5. Feb 24

   Phase 2 clinical data

   24h Move

   +16.1%

   Phase 2 results showed greater than 25% thrombotic-event reduction

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

12-lox, heparin-induced thrombocytopenia, cardiac surgery-associated acute kidney injury, out-licensing

4 terms

12-lox medical

"novel upstream targets, such as 12-LOX, that are being studied"

12-lox is an enzyme that acts like a cellular factory, turning a common fat molecule into signaling chemicals that influence inflammation, blood clotting, and cell growth. Investors watch it because drugs or tests that block or measure 12-lox activity can change outcomes for diseases such as heart disease, diabetes complications, and certain cancers, creating potential markets for therapies, diagnostics, or companion treatments.

heparin-induced thrombocytopenia medical

"CAD-1005 for both HIT and CSA-AKI"

An immune reaction to the blood-thinning drug heparin that destroys or disables platelets, the blood cells that stop bleeding, while paradoxically increasing the risk of dangerous clots. Think of it as the body’s security system misidentifying helpful staff and triggering chaos that both lowers protection and creates blockages. Investors care because it can change demand for drugs and devices, drive safety warnings or lawsuits, and affect hospital treatment costs and clinical trial outcomes.

cardiac surgery-associated acute kidney injury medical

"Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)"

Acute kidney injury that occurs after heart surgery, where the kidneys suddenly lose some filtering ability because of reduced blood flow, inflammation, or stress from the operation and recovery. Like a home water filter that clogs after heavy use, this condition is detected by rising waste levels in the blood or falling urine output and matters to investors because it can drive longer hospital stays, higher treatment costs, regulatory scrutiny of therapies and devices, and measurable impacts on healthcare and company financial results.

out-licensing financial

"strategic partnerships, including out-licensing or co-development"

Out-licensing is when a company grants another firm the right to develop, manufacture or sell a product or technology in exchange for upfront payments, milestone fees and ongoing royalties. Think of it like leasing a recipe to a larger kitchen so they handle production and sales while the original owner collects steady income and reduces costs and risk. For investors, out-licensing can speed commercialization, create near-term revenue, lower development expenses, and shift where future profits and growth will come from.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal injury
• Dual-Indication Development and Commercialization Strategy Expands the Clinical Advancement of CAD-1005 to target both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
• Addresses High-Value Gap in the Acute Care Market –First-in-class positioning in the $1 billion+ U.S. CSA-AKI market following the recent discontinuation of a competitor's late-stage Phase 3 clinical trial for lack of efficacy
• Global Partnering Potential – Leverages shared in-hospital ICU infrastructure and intravenous (IV) presentation to deliver a critical care asset package

PONTE VEDRA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced a consolidation of its multi-indication strategy for its Cardiac Acute Critical Care (CACC) Franchise, with a focus on CAD-1005 for both HIT and CSA-AKI.

Following a competitor’s recent Phase 3 failure in CSA-AKI, Cadrenal is highlighting the potential of its 12-LOX inhibitor to address a $1 billion+ market opportunity in this critical care space. CAD-1005 is being studied as a "Post-Operative Shield" that uses 12-lipoxygenase (12-LOX) inhibition intended to target platelet hyperactivation in HIT while simultaneously reducing inflammation-driven injury in patients with CSA-AKI. This dual-mechanism approach is supported by CAD-1005 clinical data presented last month at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris. The late-breaking Phase 2 data for CAD-1005 demonstrated a compelling medical profile, with an absolute reduction in thrombotic events greater than 25% and a favorable safety and renal-protective baseline.

"The recent clinical failure of a competing late-stage mechanism highlights the urgent need for novel upstream targets, such as 12-LOX, that address the root causes of cardio-renal injury," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “This trial termination underscores the ongoing clinical challenge of identifying targeted pharmacologic strategies for the treatment of CSA-AKI, as no single drug class has yet demonstrated clear preventive efficacy for the condition. The company is actively pursuing strategic partnerships, including out-licensing or co-development, to leverage its transaction-ready, Phase 3-ready asset.

About CAD-1005
CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) and orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also being evaluated for chronic indications. To view how CAD-1005 is intended to work in patients with HIT, visit https://vimeo.com/1209382706/7dde06dc08?share=copy&fl=sv&fe=ci

About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. Its lead program, CAD-1005, is being investigated as a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder, and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The Company’s Cardiac Acute Critical Care (CACC) portfolio also includes frunexian, an investigational intravenous Factor XIa inhibitor intended to provide anticoagulation for patients undergoing major cardiac surgery. 

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and atrial fibrillation, those with left ventricular assist devices, and potentially those with Kawasaki disease (KD), an acute, self-limited, febrile illness that primarily affects children under 5 years old and is the leading cause of acquired heart disease in developed countries. The Company recently submitted a request for Rare Pediatric Disease Designation (RPDD) to the FDA for tecarfarin for “Prevention of the Formation of Life-Threatening Blood Clots Inside Coronary Artery Aneurysms in Children with Kawasaki Disease”. Tecarfarin has also received Orphan Drug and Fast Track designations from the FDA.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, without limitation, statements such as the ability of the Company’s Cardiac Acute Critical Care Franchise to address a crucial unmet need; the Company leveraging shared in-hospital ICU infrastructure and identical intravenous (IV) formulations to deliver a critical care asset package; the Company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions; the potential of CAD-1005 to address a $1B+ market gap; CAD-1005 potentially using 12-LOX inhibition to target platelet hyperactivation in HIT while simultaneously reducing inflammation-driven injury in patients with CSA-AKI; 12-LOX addressing the root causes of cardio-renal injury; identifying targeted pharmacologic strategies for the treatment of CSA-AKI; the company’s pursuit of strategic partnerships, including out-licensing or co-development, to leverage its Phase 3-ready asset; CAD-1005 addressing the underlying biological mechanisms that drive disease progression; the development of second-generation 12-LOX oral therapeutics for the treatment of chronic indications; frunexian potentially providing anticoagulation for patients undergoing major cardiac surgery; tecarfarin potentially treating patients requiring chronic anticoagulation, including those with end-stage kidney disease and atrial fibrillation, those with left ventricular assist devices, and potentially those with Kawasaki disease; and the FDA’s determination with respect to the Company’s request for RPDD for tecarfarin. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to advance specialized therapies for critical care cardiology and orphan cardiovascular conditions; the ability to enter into strategic partnerships, including out-licensing or co-development, to leverage its Phase 3-ready asset; the ability of CAD-1005 to address a $1B+ market gap; the ability of 12-LOX inhibition to target platelet hyperactivation in HIT while simultaneously reducing inflammation-driven injury in patients with CSA-AKI; the ability of 12-LOX to address the root causes of cardio-renal injury; the ability to develop second-generation 12-LOX oral therapeutics for the treatment of chronic indications; the ability of frunexian to provide anticoagulation for patients undergoing major cardiac surgery; the ability of tecarfarin to treat patients requiring chronic anticoagulation, including those with end-stage kidney disease and atrial fibrillation, those with left ventricular assist; the ability of the Company to raise sufficient capital to continue the clinical development of its product candidates; and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

For more information, please contact:

Lytham Partners, LLC, Robert Blum, Managing Partner, 602-889-9700, CVKD@lythampartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cadrenal Therapeutics (CVKD) announce about its CAD-1005 strategy on August 3, 2026?

Cadrenal Therapeutics announced a consolidated multi-indication strategy for CAD-1005 in cardiac acute critical care, targeting HIT and CSA-AKI. According to Cadrenal Therapeutics, CAD-1005 is Phase 3-ready and central to its Cardiac Acute Critical Care franchise and partnering plans.

How strong were the Phase 2 results for CAD-1005 reported by Cadrenal Therapeutics (CVKD)?

Phase 2 data for CAD-1005 showed an absolute reduction in thrombotic events greater than 25%. According to Cadrenal Therapeutics, these late-breaking ISTH 2026 results also indicated a favorable safety profile and renal-protective baseline in the studied patient population.

What market opportunity is Cadrenal Therapeutics (CVKD) targeting with CAD-1005 in CSA-AKI?

Cadrenal Therapeutics is targeting a U.S. CSA-AKI market estimated above $1 billion with CAD-1005. According to Cadrenal Therapeutics, CAD-1005 aims for first-in-class positioning following a competitor’s late-stage Phase 3 trial discontinuation for lack of efficacy.

What is the mechanism of action of CAD-1005 in Cadrenal Therapeutics’ (CVKD) pipeline?

CAD-1005 is a 12-lipoxygenase (12-LOX) inhibitor being developed as a post-operative shield. According to Cadrenal Therapeutics, it is intended to reduce platelet hyperactivation in HIT and limit inflammation-driven injury in patients with CSA-AKI in critical care settings.

How is Cadrenal Therapeutics (CVKD) planning to commercialize CAD-1005 globally?

Cadrenal Therapeutics is actively pursuing strategic partnerships, including out-licensing or co-development, for CAD-1005. According to Cadrenal Therapeutics, the company aims to leverage shared in-hospital ICU infrastructure and IV presentation to create a transaction-ready, Phase 3-ready critical care asset package.

Why does Cadrenal Therapeutics (CVKD) see an urgent need for CAD-1005 in CSA-AKI?

Cadrenal cites a recent clinical failure of a competing late-stage mechanism in CSA-AKI as highlighting unmet need. According to Cadrenal Therapeutics, no single drug class has yet shown clear preventive efficacy, supporting exploration of novel upstream targets like 12-LOX.